113 related articles for article (PubMed ID: 10843486)
1. The utilization of immunohistochemical prognostic factor in endometrial adenocarcinoma: is it cost effective?
Gürer IE; Simşek T; Erdoğan G; Atalay E; Zorlu CG; Karaveli S; Erman O
Eur J Gynaecol Oncol; 2000; 21(2):197-9. PubMed ID: 10843486
[TBL] [Abstract][Full Text] [Related]
2. [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
Pilka R; Mícková I; Lubuský M; Dusková M; Rícánková M; Kudela M
Ceska Gynekol; 2008 Jul; 73(4):222-7. PubMed ID: 18711961
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of heat shock protein 27, in normal hyperplastic and neoplastic endometrium: correlation with estrogen and progesterone receptor status, p53, pRb and proliferation associated indices (PCNA, MIB1).
Zagorianakou N; Ioachim E; Mitselou A; Kitsou E; Zagorianakou P; Makrydimas G; Salmas M; Agnantis NJ
Eur J Gynaecol Oncol; 2003; 24(3-4):299-304. PubMed ID: 12807244
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
5. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
Bonfitto VL; de Angelo Andrade LA
Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity.
Yamauchi N; Sakamoto A; Uozaki H; Iihara K; Machinami R
Int J Gynecol Pathol; 1996 Jul; 15(3):202-8. PubMed ID: 8811380
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic importance of selected molecular genetic immunohistochemical markers and DNA ploidy in endometrial cancer].
Kudela M; Pilka R; Lubuský M; Hejtmánek P; Dzubák P; Brychtová S
Ceska Gynekol; 2011 Jun; 76(3):194-9. PubMed ID: 21838149
[TBL] [Abstract][Full Text] [Related]
8. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
9. The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB-1 and PC10; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade.
Nielsen AL; Nyholm HC
Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(1):79-85. PubMed ID: 9031925
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma.
Cherchi PL; Marras V; Capobianco G; Ambrosini G; Piga MD; Fadda GM; Rosas N; Dessole S
Eur J Gynaecol Oncol; 2001; 22(6):451-3. PubMed ID: 11874080
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray.
Choi DH; Kim S; Rimm DL; Carter D; Haffty BG
Cancer J; 2005; 11(5):404-11. PubMed ID: 16259871
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium.
Athanassiadou P; Petrakakou E; Liossi A; Nakopoulou L; Zerva C; Dimopoulos A; Athanassiades P
Acta Cytol; 1999; 43(6):1039-44. PubMed ID: 10578976
[TBL] [Abstract][Full Text] [Related]
13. Selected immunohistochemical prognostic factors in endometrial cancer.
Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical evaluation and lymph node metastasis in surgically staged endometrial carcinoma.
Pilka R; Marková I; Dusková M; Procházka M; Tozzi M; Kudela M
Eur J Gynaecol Oncol; 2010; 31(5):530-5. PubMed ID: 21061794
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein CD44 expression in normal, hyperplasic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1).
Zagorianakou N; Ioachim E; Mitselou A; Kitsou E; Zagorianakou P; Stefanaki S; Makrydimas G; Agnantis NJ
Eur J Gynaecol Oncol; 2003; 24(6):500-4. PubMed ID: 14658589
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma.
Soong R; Knowles S; Williams KE; Hammond IG; Wysocki SJ; Iacopetta BJ
Br J Cancer; 1996 Aug; 74(4):562-7. PubMed ID: 8761370
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral effects of medroxy-progesterone on proliferation, apoptosis, and sex steroid receptors in endometrioid endometrial adenocarcinoma.
Dahmoun M; Boman K; Cajander S; Bäckström T
Gynecol Oncol; 2004 Jan; 92(1):116-26. PubMed ID: 14751147
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes.
Kalogiannidis I; Bobos M; Papanikolaou A; Makedos A; Amplianitis I; Vergote I; Nenopoulou E; Makedos G
Eur J Gynaecol Oncol; 2008; 29(1):19-25. PubMed ID: 18386458
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
